The Gross Law Firm Announces Class Actions on Behalf of Shareholders of ACB, ICPT and PINS
Back to Newsroom
Mentioned in this Article

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of ACB, ICPT and PINS

Thursday, November 26, 2020 1:30 PM
Share this article now
Topic:
Lawsuits

NEW YORK, NY / ACCESSWIRE / November 26, 2020 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.

Aurora Cannabis Inc. (NYSE:ACB)

Investors Affected : February 13, 2020 - September 4, 2020

A class action has commenced on behalf of certain shareholders in Aurora Cannabis Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Aurora had significantly overpaid for previous acquisitions and experienced degradation in certain assets, including its production facilities and inventory; (ii) the Company's purported "business transformation plan" and cost reset failed to mitigate the foregoing issues; (iii) accordingly, it was foreseeable that the Company would record significant goodwill and asset impairment charges; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/aurora-cannabis-inc-loss-submission-form-2/?id=11242&from=1

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)

Investors Affected : September 28, 2019 - October 7, 2020

A class action has commenced on behalf of certain shareholders in Intercept Pharmaceuticals, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Defendants downplayed the true scope and severity of safety concerns associated with the use of Ocaliva (obeticholic acid ("OCA")), Intercept's lead product candidate, in treating primary biliary cholangitis; (ii) the foregoing increased the likelihood of a U.S. Food and Drug Administration ("FDA") investigation into Ocaliva's development, thereby jeopardizing Ocaliva's continued marketability and the sustainability of its sales; (iii) any purported benefits associated with OCA's efficacy in treating nonalcoholic steatohepatitis ("NASH") were outweighed by the risks of its use; (iv) as a result, the FDA was unlikely to approve the Company's New Drug Application for OCA in treating patients with liver fibrosis due to NASH; and (v) as a result of all the foregoing, the Company's public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/intercept-pharmaceuticals-inc-loss-submission-form/?id=11242&from=1

Pinterest, Inc. (NYSE:PINS)

Investors Affected : May 16, 2019 - November 1, 2019

A class action has commenced on behalf of certain shareholders in Pinterest, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's addressable market in the U.S. was reaching its maximum capacity; (ii) which significantly decelerated Pinterest's future ability to monetize on U.S. average revenue per user; (iii) Pinterest was at an increased risk of losing advertising revenue; (iv) and as a result, Defendants' public statements were materially false and misleading at all relevant times or lacked a reasonable basis and omitted material facts.

Shareholders may find more information at https://securitiesclasslaw.com/securities/pinterest-inc-loss-submission-form/?id=11242&from=1

The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (212) 537-9430
Fax: (833) 862-7770

SOURCE: The Gross Law Firm

The Gross Law Firm
Back to Newsroom
Copyright 2021 © ACCESSWIRE. All rights reserved. Privacy Policy  |  Terms and Conditions
Drop us a line: